ReviewTherapeutics and clinical risk management2015
Tapentadol extended release in the management of peripheral diabetic neuropathic pain.
Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Roles of noncoding RNAs in neuropathic pain.Pain reports · 2025Review
- Low intensity trans-spinal focused ultrasound reduces mechanical sensitivity and suppresses spinal microglia activation in rats with chronic constriction injury.Bioelectronic medicine · 2025Article
- Electroacupuncture protects against cerebral ischemia-reperfusion injury via regulating P2×7R expression.Cerebral circulation - cognition and behavior · 2025Article
- RNA Interference Unleashed: Current Perspective of Small Interfering RNA (siRNA) Therapeutics in the Treatment of Neuropathic Pain.ACS pharmacology & translational science · 2024Review
- Novel drugs affecting diabetic peripheral neuropathy.Iranian journal of basic medical sciences · 2024Review
- Application and underlying mechanism of acupuncture for the nerve repair after peripheral nerve injury: remodeling of nerve system.Frontiers in cellular neuroscience · 2023Review
- Crosstalk between Sirtuins and Nrf2: SIRT1 activators as emerging treatment for diabetic neuropathy.Metabolic brain disease · 2022Review
- Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain.Turkish journal of pharmaceutical sciences · 2022Article
- Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.Nature reviews. Endocrinology · 2021Review
- Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Review
- Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists.Therapeutics and clinical risk management · 2020Review
- Spinal αBritish journal of pharmacology · 2019Review
- Diagnosing and managing diabetic somatic and autonomic neuropathy.Therapeutic advances in endocrinology and metabolism · 2019Review
- An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy.F1000Research · 2019Review
- Testosterone deficiency in non-cancer opioid-treated patients.Journal of endocrinological investigation · 2018Review
- Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics.Drug delivery and translational research · 2018Article
- Pharmacotherapy for Neuropathic Pain: A Review.Pain and therapy · 2017Review
- Tapentadol in neuropathic pain cancer patients: a prospective open label study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- The switch from buprenorphine to tapentadol: is it worth?Romanian journal of anaesthesia and intensive care · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.